(Q38171346)

30 August 2017

title

Darunavir: a review of its use in the management of HIV-1 infection (English)

1 reference

30 August 2017

1 reference

1

Emma D Deeks

1 reference

30 August 2017

publication date

1 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

74

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

99-125

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0159-3

30 August 2017

exact match

0 references

cites work

Achieving a cure for HIV infection: do we have reasons to be optimistic?

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Paediatric HIV--trends & challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Drug resistance in HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Recent advances in antiretroviral treatment and prevention in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Darunavir: in the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Conformational analysis of TMC114, a novel HIV-1 protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Resistance profile of darunavir: combined 24-week results from the POWER trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Darunavir: in treatment-experienced pediatric patients with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Darunavir concentrations exceed the protein-corrected EC₅₀ for wild-type HIV in the semen of HIV-1-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Protease inhibitor resistance update: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Lessons from a multicentre paediatric HIV trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Tipranavir: a review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Effect of darunavir on lipid profile in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0159-3

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

21 January 2018

1 reference

12 December 2020

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.

1 reference

12 December 2020

Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial

1 reference

12 December 2020

Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.

1 reference

12 December 2020

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

1 reference

12 December 2020

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

1 reference

12 December 2020

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).

1 reference

12 December 2020

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

1 reference

12 December 2020

HIV-1 antiretroviral drug therapy

1 reference

12 December 2020

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients

1 reference

12 December 2020

Cobicistat: a new boost for the treatment of human immunodeficiency virus infection

1 reference

12 December 2020

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors

1 reference

12 December 2020

Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.

1 reference

12 December 2020

Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS

1 reference

12 December 2020

Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN

1 reference

12 December 2020

Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial

1 reference

12 December 2020

10.1007/S40265-013-0159-3

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1033873781

0 references

1 reference